I-Mab Announces Upcoming Participation at January Conferences

On December 31, 2021 I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, reported its participation in the following conferences in January 2022 (Press release, I-Mab Biopharma, DEC 31, 2021, View Source [SID1234597890]). Details of the conferences and management presentation are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

40th Annual J.P. Morgan Healthcare Conference

Presentation: Tuesday, January 11, 2022, at 4:30 p.m. E.S.T.

Presenter: Dr. Jingwu Zang, Founder, Chairman, Acting CEO and Director

Webcast link: View Source;kiosk=true The webcast will also be available under "Event Calendar" on IMAB’s IR website at View Source .

One-on-one and small group meetings: January 19-21, 2022

Management participants: Dr. Jingwu Zang, Founder, Chairman, Acting CEO and Director, Dr. Andrew Zhu, Director and President, Mr. John Long, Director and Chief Financial Officer, Mr. Tianyi Zhang, Vice President Investor Relations, Mr. Tyler Ehler, Senior Director Investor Relations and Phoebe Peng, Associate Director Investor Relations

For more information, please contact your J.P. Morgan representative.

Morgan Stanley Virtual China New Economy Summit 2022

One-on-one and small group meetings: January 5-7, 2022

Management participants: Dr. Jingwu Zang, Founder, Chairman, Acting CEO and Director, Dr. Andrew Zhu, Director and President, Mr. John Long, Director and Chief Financial Officer, Mr. Tianyi Zhang, Vice President Investor Relations, Mr. Tyler Ehler, Senior Director Investor Relations and Phoebe Peng, Associate Director Investor Relations

For more information, please contact your Morgan Stanley representative.

H.C. Wainwright Virtual BioConnect Conference

One-on-one and small group meetings: January 10 – 13, 2021

Management participants: Dr. Jingwu Zang, Founder, Chairman, Acting CEO and Director, Dr. Andrew Zhu, Director and President, Mr. John Long, Director and Chief Financial Officer, Mr. Tianyi Zhang, Vice President Investor Relations, Mr. Tyler Ehler, Senior Director Investor Relations and Phoebe Peng, Associate Director Investor Relations

For more information, please contact your H.C.Wainwright representative.

UBS Greater China Conference 2022

One-on-one and small group meetings: January 11-14, 2022

Management participants: Dr. Jingwu Zang, Founder, Chairman, Acting CEO and Director, Dr. Andrew Zhu, Director and President, Mr. John Long, Director and Chief Financial Officer, Mr. Tianyi Zhang, Vice President Investor Relations, Mr. Tyler Ehler, Senior Director Investor Relations and Phoebe Peng, Associate Director Investor Relations

For more information, please contact your UBS representative.

GenFleet Therapeutics Raises $75 Million in Series C Financing Led by Huagai Capital, to Advance Innovative Pipeline Highlighting Cutting-edge Therapies

On December 31, 2021 GenFleet Therapeutics, a clinical-stage biotechnology company with a focus in cutting-edge therapies in oncology and immunology, reported the completion of $75 million (~500 million RMB) series C financing (Press release, GenFleet Therapeutics, DEC 31, 2021, View Source [SID1234597889]). This round of financing is led by Huagai Capital, with participation by new investors including Suxin Venture Capital, Cherami Investment Group, ABC International, DYEE Capital, Qiaojing Eastern Investment, Baidu Venture, and Wenzhou Capital. Existing investors including Lake Bleu Capital, Panlin Capital, Shanjin Asset, CDH Venture and Growth Capital, HM Capital also participated. Start Point Advisors act as the sole financial advisor.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are grateful to Huagai Capital and other investors for their recognition of our strategy to develop cutting-edge therapies, our innovative discovery platform, and our differentiated pipeline in both small molecules and biologics. We believe that it is our unique strategy, platform and pipeline that can not only minimize but may even eliminate the uncertainties induced by the market fluctuations or investment cycles. We can therefore provide a sound foundation for continuous growth and to distinguish ourselves from an extremely competitive environment to bring to patients globally innovative therapies from China." said Dr. Qiang Lu, Co-founder and Chairman of GenFleet Therapeutics.

"GenFleet’s pipeline highlights our focuses in cutting-edge therapies with novel mechanisms and global IP. We have built a highly differentiated pipeline sustained by our proprietary discovery platform. As we expect more programs to move into late-stage clinical development in 2022, GenFleet will continue to march toward commercialization and globalization. We hope to help patients across the world through scientific breakthroughs and achieve positive financial results for our stakeholders." said Dr. Jiong Lan, Co-founder and Chief Executive Officer of GenFleet Therapeutics.

"HuaGai Capital feels honored to join GenFleet and to lead this round of financing. GenFleet is dedicated to serving unmet medical needs and we are impressed with its industry-leading progress as well as its efficient execution. Under the leadership of Dr. Lu and Dr. Lan, GenFleet truly stands out among competitors to bring life-saving treatments and better healthcare solutions to global patients." said Zhiqiang Zeng, Managing Partner of HuaGai Healthcare.

"We are pleased to lead this round of financing. GenFleet has established its proprietary R&D platform based on the deep understanding of disease biology and translational medicine. Its cutting-edge portfolio highlights innovative therapies with global IP, and we look forward to its prospects of globalization and long-term development in the industry." said Jingyang Zhu, Vice President of HuaGai Healthcare.

Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering

On December 30, 2021 Akari Therapeutics, Plc (Nasdaq: AKTX) ("Akari" or the "Company"), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, reported that it has entered into definitive agreements with institutional investors and accredited investors, led by existing investors of the Company, including Dr. Ray Prudo, the Company’s Chairman, to receive gross proceeds of approximately $6.0 million (Press release, Akari Therapeutics, DEC 30, 2021, View Source [SID1234598027]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In connection with the offering, the Company will issue approximately 4,310,839 registered American Depository Shares (ADSs) of Akari at a purchase price of $1.40 per ADS in a registered direct offering. Additionally, for each ADS purchased by investors, the investors will receive a registered warrant to purchase one-half ADS. The warrants will have an exercise price of $1.65 per ADS, will be exercisable upon their issuance and will expire five years from the issuance date. The closing of the offering is expected to take place on or about January 4, 2022, subject to the satisfaction of customary closing conditions.

Paulson Investment Company, LLC, is acting as the exclusive placement agent in connection with this offering.

The securities described above are being offered by Akari pursuant to an effective shelf registration statement on Form F-3 (File No. 333-251673) previously filed with the Securities and Exchange Commission (the "SEC") on December 23, 2020 and declared effective by the SEC on December 31, 2020. The offering of the securities will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

The Company will file a prospectus supplement and the accompanying base prospectus with the SEC relating to the securities being offered. When available, electronic copies of the prospectus supplement and the accompanying base prospectus may be obtained at the SEC’s website at View Source, or by contacting Donald A. Wojnowski Jr. of Paulson Investment Company, LLC, at (855) 653-3444 or at [email protected]

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Entry into a Material Definitive Agreement

On December 30, 2021, Personalis, Inc., or the Company, reported that entered into an At-the-Market Sales Agreement, or the Sales Agreement, with BTIG, LLC, or BTIG, under which it may offer and sell its common stock having aggregate sales proceeds of up to $100.0 million from time to time through BTIG as its sales agent (Filing, 8-K, Personalis, DEC 30, 2021, View Source [SID1234597952]). Sales of the Company’s common stock through BTIG, if any, will be made by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including without limitation sales made directly on the Nasdaq Global Market or any other existing trading market for its common stock. BTIG will use commercially reasonable efforts to sell the Company’s common stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay BTIG a commission of up to 3.0% of the gross sales proceeds of any common stock sold through BTIG under the Sales Agreement. The Company has also provided BTIG with customary indemnification rights.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company is not obligated to make any sales of common stock under the Sales Agreement. The offering of shares of the Company’s common stock pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the Sales Agreement, or (ii) termination of the Sales Agreement in accordance with its terms.

The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference. This Current Report on Form 8-K also incorporates by reference the Sales Agreement into the Registration Statement (as defined below).

The Company’s common stock is being offered and sold pursuant to the Company’s effective shelf registration statement on Form S-3 and an accompanying prospectus (Registration Statement No. 333-251824) declared effective by the U.S. Securities and Exchange Commission, or SEC, on January 8, 2021, or the Registration Statement, and a prospectus supplement dated December 30, 2021.

Mission Bio and SequMed Sign Collaboration Agreement Announcing Partnership to Provide Tapestri Services and Co-Develop Clinical Applications in China

On December 30, 2021 Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, reported that it has signed an agreement with SequMed, a pioneer in single-cell omics technology innovation and applications in China (Press release, Mission Bio, DEC 30, 2021, View Source [SID1234597860]). The agreement will allow Mission Bio to expand its product and services offerings into China, a key region of growth for its geographical expansion strategy, enabling high quality single-cell sequence services using Mission Bio’s products to customers in mainland China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With this new and important collaboration, Mission Bio and SequMed will work jointly by integrating Mission Bio’s technology platform into SequMed’s clinical assay development and data analysis capabilities to co-develop novel single cell assays for early detection, medication guidance, and prognostic monitoring of cancers, as well as reproductive genetics applications. This partnership builds on Mission Bio’s commitment to providing high quality single-cell multi-omics with the Tapestri platform in China, where there is an increasing demand for single-cell innovation for clinical diagnosis.

"Tumor heterogeneity is always one of the biggest challenges for cancer therapy and the development of treatment resistance," said Yan Zhang, CEO of Mission Bio. "Our Tapestri single-cell sequencing solutions enable us to detect the co-occurring mutations within cancer cells, allowing us to understand the mechanisms of resistance at a granular level. We are excited to collaborate with SequMed. By integrating our single-cell technology with SequMed’s expertise in clinical assay development, we are committed to improving diagnosis, prognosis, and treatment of diseases in China."

Prof. Xinghua Victor Pan, Chairman of Technology Committee of SequMed, said, "We are dedicated to promoting the development and application of next-generation single-cell multi-omics technology in scientific and clinical research. We look forward to working with Mission Bio to develop novel single-cell assays for different diseases, from molecular mechanism elucidation to clinical medicine acceleration. With the synergies between the two collaborating parties, SequMed will enter into a new era, providing our customers in China with comprehensive solutions for personalized medicine."